Skip to main content
Equibles
NUVB logo

NUVB · Nuvation Bio Inc. · Metrics

Track NUVB — free

Use NUVB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NUVB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.57 -0.13 (-2.77%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.60B
Shares
351.12M
Volume · Oct 23 3.19M Avg daily vol (3M) 5.41M

NUVB metrics

80 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.57
Market cap
$1.60B

Price action

20 metrics
Price change (1W)
+2.7%
Price change (30D)
-20.4%
Price change (3M)
-28.8%
Price change (6M)
-6.5%
Price change (YTD)
-49.0%
Price change (1Y)
+4.1%
Trailing year
Price change (5Y)
-51.1%
52-week high
$9.54
52-week low
$4.05
Change from 52-week high
-52.1%
Change from 52-week low
+12.8%
Annualized volatility
82.9%
Annualized volatility (3M)
54.1%
Beta
1.7
RSI (14D)
33.7
Price vs SMA 50
-21.8%
Price vs SMA 200
-16.3%
Avg volume (3M)
5.41M
Relative volume
0.6
Average dollar volume
$32.24M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
351.12M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.0×
reciprocal yield 14.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
9.4×
reciprocal yield 10.6%
P / book
6.3
reciprocal yield 15.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
21.3×
reciprocal yield 4.7%
EV / revenue historical average (5Y)
21.3×
reciprocal yield 4.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-81.0%
Trailing 12 months
Net margin
-88.2%
Gross profit (TTM)
$14.51M
Operating profit (TTM)
−$137.63M
Net income (TTM)
−$149.83M
Trailing 12 months
Diluted EPS (TTM)
$-0.44
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$471.21
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-399.72
EBITDA per diluted share (TTM)
$-393.64
Net income per diluted share (TTM)
$-435.09
Operating cash flow per diluted share (TTM)
$-350.59
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$364.60
Stock compensation per diluted share (TTM)
$100.54
Book value per share
$0.88

Growth

11 metrics
Revenue growth YoY
+555.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$169.90M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-59.0%
Return on assets
-20.1%
Debt / equity
1.0
Current ratio
8.4
EBITDA (TTM)
−$135.48M
Free cash flow (TTM)
—
Quick ratio
8.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$412.44M
Latest balance sheet
Cash & equivalents
$258.60M
Total assets
$744.50M
Total debt
$248.52M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$120.52M
Capital expenditures (TTM)
—
R&D (TTM)
$128.85M
SG&A (TTM)
$158.59M
Stock compensation (TTM)
$35.50M
R&D / revenue
75.8%
Stock compensation / revenue
20.9%

Ownership (13F)

9 metrics
13F filers
245
13F filer change QoQ
+10
Institutional ownership
68.4%
Conviction holders (share of 13F filers)
2.0%
Crowding (high-turnover and private-fund holders)
16.8%
Private-fund adviser ownership
13.8%
Active holders' share change QoQ
+5.7%
Holder tenure
13.0
Price vs estimated holder cost
+10.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.5%

Short interest

3 metrics
Short interest
16.8%
Latest settlement · 13.9 days to cover
Days to cover
13.9d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$709,240
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1811063 CUSIP 67080N101 13F (30d) 30 filings 30 filers Visit website Investor relations